Elevation Oncology, Inc. financial data

Symbol
ELEV on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
101 Federal Street, Suite 1900, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
14ner Oncology, Inc. (to 7/19/2019)
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.8 K % +183%
Debt-to-equity 54 % -9.41%
Return On Equity -59.4 % +60.2%
Return On Assets -38.5 % +58.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.6 M shares +131%
Common Stock, Shares, Outstanding 51.7 M shares +117%
Entity Public Float 52.8 M USD +137%
Common Stock, Value, Issued 5 K USD +150%
Weighted Average Number of Shares Outstanding, Basic 47.4 M shares +101%
Weighted Average Number of Shares Outstanding, Diluted 47.4 M shares +101%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.2 M USD -66.7%
General and Administrative Expense 14.4 M USD -12%
Operating Income (Loss) -38.6 M USD +58.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.3 M USD +58.5%
Income Tax Expense (Benefit) 36 K USD +20%
Net Income (Loss) Attributable to Parent -39.4 M USD +58.5%
Earnings Per Share, Basic -0.85 USD/shares +79.1%
Earnings Per Share, Diluted -0.85 USD/shares +79.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 90.6 M USD +62.1%
Marketable Securities, Current 13.4 M USD -25.6%
Assets, Current 108 M USD +42.3%
Property, Plant and Equipment, Net 49 K USD -44.3%
Other Assets, Noncurrent 1.03 M USD +5.13%
Assets 109 M USD +41.7%
Accounts Payable, Current 435 K USD -89.2%
Accrued Liabilities, Current 1.9 M USD -80%
Liabilities, Current 2.33 M USD -82.8%
Liabilities 33.1 M USD -23.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -207 M USD -23.5%
Stockholders' Equity Attributable to Parent 75.8 M USD +125%
Liabilities and Equity 109 M USD +41.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.58 M USD +43.1%
Net Cash Provided by (Used in) Financing Activities 30.3 M USD +13905%
Net Cash Provided by (Used in) Investing Activities 20.7 M USD -22.2%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 51.7 M shares +117%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.4 M USD +314%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 90.6 M USD +62.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 887 K USD +66.7%
Deferred Tax Assets, Valuation Allowance 45.9 M USD +30.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 45.9 M USD +30.4%
Depreciation 10 K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39.3 M USD +58.5%
Deferred Tax Assets, Operating Loss Carryforwards 20.2 M USD +62.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 283 M USD +40.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3 K USD -62.5%
Share-based Payment Arrangement, Expense 2.77 M USD -31.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%